M

MEI Pharma
D

MEIP

3.13000
USD
0.00
(0.00%)
Market Closed
Volume
850
EPS
0
Div Yield
0
P/E
1
Market Cap
20,854,742
OverviewSignalsIdeasNews
Related Instruments
    A
    ARWR
    -1.160
    (-4.06%)
    27.410 USD
    B
    BPMC
    -8.610
    (-7.94%)
    99.770 USD
    C
    CRVS
    0.36000
    (13.85%)
    2.96000 USD
    E
    EXEL
    0.740
    (3.15%)
    24.200 USD
    F
    FATE
    -0.46000
    (-8.61%)
    4.88000 USD
    H
    HRTX
    -0.17000
    (-5.72%)
    2.80000 USD
    I
    INFI
    -0.046100
    (-55.54%)
    0.036900 USD
    M
    MRTX
    0
    (0%)
    0.000000 USD
    More
News

Title: MEI Pharma

Sector: Healthcare
Industry: Biotechnology
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.